Results 11 to 20 of about 66,232 (237)

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study [PDF]

open access: yes, 2010
Objectives: To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom.
Sheasby, E   +52 more
core   +1 more source

A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. [PDF]

open access: yes, 2010
BACKGROUND: The emergence of drug resistant typhoid fever is a major public health problem, especially in Asia. An oral single dose typhoid vaccine would have major advantages.
Schultsz, C   +162 more
core   +2 more sources

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity [PDF]

open access: yes, 2012
© 2012 Elsevier Ltd. All rights reservedBackground: The development of a new, more effective vaccine against tuberculosis (TB) for use in healthy and HIV-infected adults, children and infants, remains a global health priority.
Minassian, Angela M   +32 more
core   +1 more source

Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. [PDF]

open access: yes, 2014
BACKGROUND: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placebo-controlled trial, the safety and immunogenicity of ...
Said, Khadija   +67 more
core   +1 more source

Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance

open access: yesJournal of Immunology Research, 2016
Numbers of biotherapeutic products in development have increased over past decade. Despite providing significant benefits to patients with unmet needs, almost all protein-based biotherapeutics could induce unwanted immunogenicity, which result in a loss ...
Sam Song   +3 more
doaj   +1 more source

Learn–confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2023
Immunogenicity against therapeutic proteins frequently causes attrition owing to its potential impact on pharmacokinetics, pharmacodynamics, efficacy, and safety.
Linnea C. Franssen   +5 more
doaj   +1 more source

Trastuzumab immunogenicity development in patients’ sera and in laboratory animals

open access: yesBMC Immunology, 2021
Background Immunogenicity is a major challenge in drug development and patient care. Clinicians and regulators are familiar with immunogenicity concerns of monoclonal antibody (mAb) therapeutics, growth factors and enzyme replacements.
Lobna Abdel Aziz Kilany   +3 more
doaj   +1 more source

Randomized, Controlled Trial of the Long Term Safety, Immunogenicity and Efficacy of RTS,S/AS02(D) Malaria Vaccine in Infants Living in a Malaria-Endemic Region. [PDF]

open access: yes, 2013
The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization.
Machera, Francisca   +104 more
core   +1 more source

Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo [PDF]

open access: yes, 2004
Strategies to enhance the immunogenicity of tumors are urgently needed. Although vaccination with irradiated dying lymphoma cells recruits a tumor-specific immune response, its efficiency as immunogen is poor.
Zimmermann, VS   +58 more
core   +1 more source

Properties of MHC class I presented peptides that enhance immunogenicity. [PDF]

open access: yesPLoS Computational Biology, 2013
T-cells have to recognize peptides presented on MHC molecules to be activated and elicit their effector functions. Several studies demonstrate that some peptides are more immunogenic than others and therefore more likely to be T-cell epitopes. We set out
Jorg J A Calis   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy